Abstract
The recognition of a foreign protein (antigen) by host B and/or T cells and the induction of immune response have a key role for the human immune system. The peptide binding to MHC proteins is a prerequisite for B or T-cell recognition. Determining the peptide-binding preferences exhibited by the MHC extensive set of alleles requires enormous experimental work. A more rational approach is the development of bioinformatics prediction methodologies. Among others, proteochemometrics (PCM) is quite suitable for MHC binding prediction as it simultaneously models the bioactivity of multiple ligands against multiple protein targets. Handling multiple targets is the key to "ligand polypharmacology" and the development of multi-target drugs. The few applications of PCM for MHC binding prediction showed that the developed models have excellent predictive ability
Keywords: Immunoinformatics, proteochemometrics, HLA-DRB1, HLA-DQ, peptide binding, MHC binders.
Letters in Drug Design & Discovery
Title:Proteochemometrics for the Prediction of Binding to the MHC Proteins
Volume: 14 Issue: 1
Author(s): Ventsislav Yordanov, Ivan Dimitrov and Irini Doytchinova
Affiliation:
Keywords: Immunoinformatics, proteochemometrics, HLA-DRB1, HLA-DQ, peptide binding, MHC binders.
Abstract: The recognition of a foreign protein (antigen) by host B and/or T cells and the induction of immune response have a key role for the human immune system. The peptide binding to MHC proteins is a prerequisite for B or T-cell recognition. Determining the peptide-binding preferences exhibited by the MHC extensive set of alleles requires enormous experimental work. A more rational approach is the development of bioinformatics prediction methodologies. Among others, proteochemometrics (PCM) is quite suitable for MHC binding prediction as it simultaneously models the bioactivity of multiple ligands against multiple protein targets. Handling multiple targets is the key to "ligand polypharmacology" and the development of multi-target drugs. The few applications of PCM for MHC binding prediction showed that the developed models have excellent predictive ability
Export Options
About this article
Cite this article as:
Yordanov Ventsislav, Dimitrov Ivan and Doytchinova Irini, Proteochemometrics for the Prediction of Binding to the MHC Proteins, Letters in Drug Design & Discovery 2017; 14 (1) . https://dx.doi.org/10.2174/1570180813666160630122341
DOI https://dx.doi.org/10.2174/1570180813666160630122341 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Drug Conjugates Using Different Dynamic Covalent Bonds and their Application in Cancer Therapy
Current Drug Delivery Tip60: Main Functions and Its Inhibitors
Mini-Reviews in Medicinal Chemistry Soy Isoflavones and Exercise: Possible Benefits for Postmenopausal Womens Cardiovascular Health
Current Women`s Health Reviews Chitosan and Quercetin: Potential Hand in Hand Encountering Tumors in Oral Delivery System
Current Pharmaceutical Design Metabolic Features of Melanoma: A Gold Mine of New Therapeutic Targets?
Current Cancer Drug Targets Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism Computational and Statistical Methods to Explore the Various Dimensions of Protein Evolution
Current Bioinformatics Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor
Current Clinical Pharmacology Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Curcumin and Genistein: the Combined Effects on Disease-associated CFTR Mutants and their Clinical Implications
Current Pharmaceutical Design The Potential of Quality Target Product Profile in the Optimization of Nanoemulsions
Current Nanomedicine Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells
Current Stem Cell Research & Therapy CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up
Current Pharmaceutical Design Quinone Methides as DNA Alkylating Agents: An Overview on Efficient Activation Protocols for Enhanced Target Selectivity
Current Organic Chemistry Recent Advances in Artemisinin Production Through Heterologous Expression
Current Medicinal Chemistry An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Soluble Factors of Amnion-Derived Cells in Treatment of Inflammatory and Fibrotic Pathologies
Current Stem Cell Research & Therapy